KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $2.5 billion.

  • Takeda Pharmaceutical's Cash & Equivalents fell 1691.27% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year decrease of 1691.27%. This contributed to the annual value of $2.5 billion for FY2025, which is 2035.73% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Cash & Equivalents of $2.5 billion as of Q4 2025, which was down 1691.27% from $2.6 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Cash & Equivalents high stood at $9.1 billion for Q1 2021, and its period low was $2.4 billion during Q2 2025.
  • In the last 5 years, Takeda Pharmaceutical's Cash & Equivalents had a median value of $3.8 billion in 2023 and averaged $4.9 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 6095.37% in 2021, then tumbled by 4483.39% in 2023.
  • Over the past 5 years, Takeda Pharmaceutical's Cash & Equivalents (Quarter) stood at $8.5 billion in 2021, then dropped by 29.24% to $6.0 billion in 2022, then tumbled by 39.99% to $3.6 billion in 2023, then fell by 16.57% to $3.0 billion in 2024, then decreased by 16.91% to $2.5 billion in 2025.
  • Its Cash & Equivalents was $2.5 billion in Q4 2025, compared to $2.6 billion in Q3 2025 and $2.4 billion in Q2 2025.